Artivion Announces Presentation Of Real World Data From Post Market Study Of On-X Aortic Heart Valve Replacement Patients Treated With Low Dose Warfarin
Portfolio Pulse from Benzinga Newsdesk
Artivion has announced the presentation of real-world data from a post-market study of On-X Aortic Heart Valve Replacement patients treated with low dose Warfarin. The data was presented at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting.
October 05, 2023 | 8:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Artivion's presentation of real-world data from a post-market study of On-X Aortic Heart Valve Replacement patients could potentially impact the company's stock.
The presentation of positive real-world data can often lead to increased confidence in a company's products, potentially leading to an increase in stock price. However, the exact impact will depend on the details of the data presented and the market's reaction to it.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100